--- title: "The Hong Kong Stock Connect Medical ETF Penghua is on the rise, with continuous catalysts in the innovative drug sector" type: "News" locale: "en" url: "https://longbridge.com/en/news/279206433.md" description: "The Penghua CSI HK Connect Health Care Composite ETF rose by 0.33%, with the latest price reported at 0.6 yuan. The pharmaceutical sector is active, with the launch of a major national science and technology project focusing on the research and development of drugs for Alzheimer's disease. Guolian Minsheng Securities pointed out that the pharmaceutical sector has entered a bottoming and recovery phase, lacking major catalytic clues in the short term, but expectations for overseas sales are high. The CSI HK Equities Medical and Health Integration Index rose by 0.52%, with the top ten weighted stocks accounting for a total of 65.08%" datetime: "2026-03-16T05:09:17.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/279206433.md) - [en](https://longbridge.com/en/news/279206433.md) - [zh-HK](https://longbridge.com/zh-HK/news/279206433.md) --- # The Hong Kong Stock Connect Medical ETF Penghua is on the rise, with continuous catalysts in the innovative drug sector The pharmaceutical sector is active during the trading session. On March 12, the launch meeting for the national key technology innovation project "Research on Chemically Innovative Drugs Targeting New Mechanisms for Alzheimer's Disease," led by the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, was held in Shanghai. The launch of this national key technology project focuses on the direction of drug research and development for chemically innovative drugs targeting new mechanisms, aiming to break through existing technical bottlenecks and build a more comprehensive drug research and development system for Alzheimer's disease. In addition, with the ASCO conference approaching in May, several Chinese innovative pharmaceutical companies will disclose key clinical data. Guotai Junan Securities pointed out that the pharmaceutical sector has entered a bottoming and repairing stage under multiple factors. Although there is a lack of major catalytic clues in the short term, companies with high expectations for overseas sales and recent clinical or business development catalysts have seen their valuations recover; in the medium term, the logic of technological innovation continues to spread, with the upstream supply chain (CRO/CDMO/bioreagents) and the four major tracks from 0 to 1 (medical robots, small nucleic acids, brain-computer interfaces, AI+) remaining the main lines. By 2026, the underlying logic of the industry will focus on three major interpretative paths: innovation, overseas expansion, and the reversal of difficulties. As of March 16, 2026, at 10:56, the CSI Hong Kong Connect Medical and Health Integration Index (930965) rose by 0.52%. Component stocks such as JD Health rose by 3.67%, InnoCare Pharma-B rose by 3.48%, CanSino Biologics rose by 2.81%, Kelun-Biotech rose by 2.48%, and CSPC Pharmaceutical Group rose by 2.33%. The Hong Kong Connect Medical ETF Penghua (513700) rose by 0.33%, with the latest price reported at 0.6 yuan. The Hong Kong Connect Medical ETF Penghua closely tracks the CSI Hong Kong Connect Medical and Health Integration Index, which selects 50 liquid and large-cap listed companies in the medical and health industry from the Hong Kong Connect range as index samples to reflect the overall performance of listed companies in the medical and health sector within the Hong Kong Connect scope. Data shows that as of February 27, 2026, the top ten weighted stocks in the CSI Hong Kong Connect Medical and Health Integration Index (930965) are WuXi Biologics, Innovent Biologics, BeiGene, CSPC Pharmaceutical Group, CanSino Biologics, JD Health, China National Pharmaceutical Group, Hansoh Pharmaceutical, WuXi AppTec, and 3SBio, with the top ten weighted stocks accounting for a total of 65.08%. The Hong Kong Connect Medical ETF Penghua (513700) has off-exchange connections (A: 021088; C: 021089; I: 022844) ### Related Stocks - [159137.CN](https://longbridge.com/en/quote/159137.CN.md) - [513700.CN](https://longbridge.com/en/quote/513700.CN.md) - [159929.CN](https://longbridge.com/en/quote/159929.CN.md) - [513200.CN](https://longbridge.com/en/quote/513200.CN.md) ## Related News & Research - [DOJ Launches Criminal Probe Into Blue State Hospital](https://longbridge.com/en/news/286157785.md) - [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md) - [Hong Kong's New Medical Watchdog to Help Chinese Mainland Innovative Drugs Hit SAR's Market Quicker, Official Says](https://longbridge.com/en/news/286736420.md) - [Manulife Singapore to offer multi-cancer blood test starting May](https://longbridge.com/en/news/286710691.md) - [09:35 ETOpen Medicine Launches Ahead of ASCO, Introducing "Living Algorithms" for Real-Time Oncology Decision-Making](https://longbridge.com/en/news/286923155.md)